Management of No-Reflow Phenomenon in the Catheterization Laboratory

JACC: Cardiovascular Interventions

Volumn 10, Issue 3, 2017, Pages 215-223

  Rezkalla, Shereif H ^a   Stankowski, Rachel V ^a   Hanna, Jennifer ^b   Kloner, Robert A ^c,d  

^a MARSHFIELD CLINIC   (United States)

^b LUND UNIVERSITY   (Sweden)

^c HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

no reflow; percutaneous coronary intervention; ST segment elevation myocardial infarction

Indexed keywords

ADENOSINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DABIGATRAN; DILTIAZEM; EPINEPHRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICARDIPINE; NICORANDIL; NITROPRUSSIDE SODIUM; VASODILATOR AGENT; VERAPAMIL;

ARTIFICIAL EMBOLIZATION; BALLOON CATHETERIZATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BLOOD FLOW; DOPPLER ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART MUSCLE REVASCULARIZATION; HUMAN; INDUCED HYPOTHERMIA; LABORATORY; NO REFLOW PHENOMENON; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; THROMBUS ASPIRATION; ADVERSE EFFECTS; ANIMAL; DRUG EFFECTS; NO-REFLOW PHENOMENON; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK FACTOR; ST ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CARDIAC CATHETERIZATION; CORONARY CIRCULATION; HUMANS; NO-REFLOW PHENOMENON; PREDICTIVE VALUE OF TESTS; RISK FACTORS; ST ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 85011850425     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.11.059     Document Type: Review

References (82)

1. 1 Kloner, R.A., Ganote, C.E., Jennings, R.B., The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest 54 (1974), 1496–1506.
2. 2 Schofer, J., Montz, R., Mathey, D.G., Scintigraphic evidence of the “no reflow” phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol 5 (1985), 593–598.
3. 3 Kloner, R.A., No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther 16 (2011), 244–250.
4. 4 Rezkalla, S.H., Kloner, R.A., No-reflow phenomenon. Circulation 105 (2002), 656–662.
5. 5 Bouleti, C., Mewton, N., Germain, S., The no-reflow phenomenon: state of the art. Arch Cardiovasc Dis 108 (2015), 661–674.
6. 6 Fugit, M.D., Rubal, B.J., Donovan, D.J., Effects of intracoronary nicardipine, diltiazem, and verapamil on coronary blood flow. J Invasive Cardiol 12 (2000), 80–85.
7. 7 Ertl, G., Frantz, S., Healing after myocardial infarction. Cardiovasc Res 66 (2005), 22–32.
8. 8 Bolognese, L., Carrabba, N., Parodi, G., et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 109 (2004), 1121–1126.
9. 9 Ndrepepa, G., Tiroch, K., Fusaro, M., et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 55 (2010), 2383–2389.
10. 10 Wu, K.C., Zerhouni, E.A., Judd, R.M., et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97 (1998), 765–772.
11. 11 Gibson, C.M., Murphy, S.A., Rizzo, M.J., et al., Thrombolysis in Myocardial Infarction (TIMI) Study Group. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation 99 (1999), 1945–1950.
12. 12 Gibson, C.M., Dotani, M.I., Murphy, S.A., et al. Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial: Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Am Heart J 144 (2002), 130–135.
13. 13 Durante, A., Camici, P.G., Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol 187 (2015), 273–280.
14. 14 Rezkalla, S.H., Dharmashankar, K.C., Abdalrahman, I.B., Kloner, R.A., No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol 23 (2010), 429–436.
15. 15 Malmberg, K., Rydén, L., Efendic, S., et al. Randomized trial of insulin-glucose infusion following by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26 (1995), 57–65.
16. 16 Di Carli, N.F., Janisse, J., Grunberger, G., Ager, J., Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 41 (2003), 1387–1393.
17. 17 Iwakura, K., Ito, H., Ikushima, M., et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 41 (2003), 1–7.
18. 18 Li, X.D., Yang, Y.J., Hao, Y.C., et al. Effects of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis. Chin Med J (Engl) 126 (2013), 1755–1760.
19. 19 Pantsios, C., Kapelios, C., Vakrou, S., et al. Effect of elevated reperfusion pressure on “no reflow” area and infarct size in a porcine model of ischemia-reperfusion. J Cardiovasc Phatmacol Ther 21 (2016), 405–411.
20. 20 Ipek, G., Onuk, T., Karatas, M.B., et al. CHA2DS2-VASc score is a predictor of no-reflow in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous intervention. Angiology 67 (2016), 840–845.
21. 21 Kurtul, A., Murat, S.N., Yarliogluez, M., Duran, M., Celik, I.E., Kilic, A., Mild to moderate renal impairment is associated with no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. Angiology 66 (2015), 644–651.
22. 22 Kurtul, A., Yarlioglues, M., Celik, I.E., et al. Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis 26 (2015), 706–712.
23. 23 Amano, H., Ikeda, T., Toda, M., et al. Plaque composition and no-reflow phenomenon during percutaneous coronary intervention of low-echoic structures in grayscale intravascular ultrasound. Int Heart J 57 (2016), 285–291.
24. 24 Suda, A., Namiuchi, S., Kawaguchi, T., et al. A simple and rapid method for identification of lesions at high risk for the no-reflow phenomenon immediately before elective coronary stent implantation. Heart Vessels 31 (2016), 1904–1914.
25. 25 Magro, M., Springeling, T., Jan van Geuns, R., Zijlstra, F., Mycoardial ‘no-reflow’ prevention. Curr Vasc Pharmacol 11 (2013), 263–277.
26. 26 Ito, H., No-reflow phenomenon in patients with acute myocardial infarction: its pathophysiology and clinical implications. Act Med Okayama 63 (2009), 161–168.
27. 27 Svilaas, T., Vlaar, P.J., van der Horst, I.C., et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358 (2008), 557–567.
28. 28 De Vita, M., Burzotta, F., Biondi-Zoccai, G.G., et al. Individual patient-date meta-analysis comparing clinical outcome in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention with or without prior thrombectomy. ATTEMPT study: a pooled Analysis of Trials on ThrombEctomy in Acute Myocardial infarction based on individual PatienT data. Vasc Health Risk Manag 5 (2009), 243–247.
29. 29 Mongeon, F.P., Bélisle, P., Joseph, L., Eisenberg, M.J., Rinfret, S., Adjunctive thrombectomy for acute myocardial infarction: a Bayesian meta-analysis. Circ Cardiovasc Interv 3 (2010), 6–16.
30. 30 Awadalla, H., Salloum, J., Moustapha, A., et al. Rheolytic thrombectomy does not prevent slow-, no-reflow during percutaneous coronary intervention in acute myocardial infarction. Int J Angiol 12 (2003), 183–187.
31. 31 Mancini, J.G., Filion, K.B., Windle, S.B., Habib, B., Eisenberg, M.J., Meta-analysis of the long-term effect of routine aspiration thrombectomy in patients undergoing primary percutaneous coronary intervention. Am J Cardiol 118 (2016), 23–31.
32. 32 Jolly SS. When Should Thrombectomy Be Performed During Primary PCI? American College of Cardiology. Latest in Cardiology. 2015. Available at: http://www.acc.org/latest-in-cardiology/articles/2015/12/10/13/19/when-should-thrombectomy-be-performed-during-primary-pci. Accessed October 7, 2016.
33. 33 Grygier, M., Araszkiewicz, A., Lesiak, M., Grajek, S., Role of adenosine as an adjunct therapy in the prevention and treatment of no-reflow phenomenon in acute myocardial infarction with ST segment elevation: review of the current data. Kardiologia Polsa 71 (2013), 115–120.
34. 34 Fischell, T.A., Maheshewari, A., Current applications for nicardipine in invasive and interventional cardiology. J Invas Cardiol 16 (2004), 428–432.
35. 35 Wang, H.J., Lo, P.H., Lin, J.J., et al. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 63 (2004), 171–176.
36. 36 Johnson-Cox, H.A., Yang, D., Ravid, K., Physiological implications of adenosine receptor-mediated platelet aggregation. J Cell Physiol 226 (2011), 46–51.
37. 37 Mahaffey, K.W., Puma, J.A., Barbagelata, N.A., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial. J Am Coll Cardiol 34 (1999), 1711–1720.
38. 38 Ross, A.M., Gibbons, R.J., Stone, G.W., Kloner, R.A., Alexander, R.W., AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45 (2005), 1775–1780.
39. 39 Kloner, R.A., Forman, M.B., Gibbons, R.J., Ross, A.M., Alexander, R.W., Stone, G.W., Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 27 (2006), 2400–2405.
40. 40 Fischell, T.A., Carter, A.J., Foster, M.T., et al. Reversal of “no-reflow” during vein graft stenting using high velocity boluses of intracoronary adenosine. Cath Cardiovasc Diagn 45 (1998), 360–365.
41. 41 Niccoli, G., Rigattieri, S., De Vita, M.R., et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the intervention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). J Am Coll Cardiol Intv 6 (2013), 580–589.
42. 42 Niccoli, G., Spaziani, C., Crea, F., REOPEN-AMI Investigators. Left ventricular remodeling and 1-year clinical follow-up of the REOPEN-AMI trial. J AM Coll Cardiol 63 (2014), 1454–1455.
43. 43 Zhang, H., Tian, N.L., Hu, Z.Y., et al. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl) 125 (2012), 1713–1719.
44. 44 Navarese, E.P., Buffon, A., Andreotti, F., et al. Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. Atherosclerosis 222 (2012), 1–7.
45. 45 Pollimeni, A., De Rosa, S., Sabatino, J., Sorrentino, S., Indolfi, C., Impact of intracoronary adenosine administration during primary PCI: a meta-analysis. Int J Cardiol 203 (2016), 1032–1041.
46. 46 Gao, Q., Yang, B., Guo, Y., Zheng, F., Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a PRISMA-compliant meta-analysis. Medicine (Baltimore), 94, 2015, e1279.
47. 47 Nazir, S.A., Khan, J.N., Mahmoud, I.Z., et al. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial. Trials, 15, 2014, 371.
48. 48 Yetgin, T., Uitterdijk, A., te Lintel Hekkert, M., et al. Limitation of infarct size and no-reflow by intracoronary adenosine depends critically on dose and duration. J Am Coll Cardiol Intv 8 (2015), 1990–1999.
49. 49 Kloner, R.A., DeBoer, L.W., Carlson, N., Braunwald, E., The effect of verapamil on myocardial ultrastructure during and following release of coronary artery occlusion. Exp Mol Pathol 36 (1982), 277–286.
50. 50 Michaels, A.D., Appleby, M., Otten, M.H., et al. Pretreatment with intracoronary verapamil prior to percutaneous coronary intervention in saphenous vein graft lesions: results of the randomized, controlled Vasodilator Prevention Of no-Reflow (VAPOR) trail. J Invas Cardiol 14 (2002), 299–302.
51. 51 Chouairi, S., Carrie, D., Puel, J., Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. Eur Heart J 16 (1995), 3–8.
52. 52 Reinstadler, S.J., Stiermaier, T., Fuernau, G., et al. The challenges and impact of microvascular injury in ST-elevation myocardial infarction. Expert Rev Cardiovasc Ther 14 (2016), 431–443.
53. 53 Umemura, S., Nakamura, S., Sugiura, T., et al. The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographic no-reflow after primary percutaneous intervention. Nucl Med Commun 27 (2006), 247–254.
54. 54 Huang, R.I., Patel, P., Walinsky, P., et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv 68 (2006), 671–676.
55. 55 Huang, D., Qian, J., Ge, L., et al. REstoration of COronary flow in patients with no-reflow after primary coronary interVEntion of acute myocaRdial infarction (RECOVER). Am Heart J 164 (2012), 394–401.
56. 56 Fu, Q., Lu, W., Huang, Y.J., et al. Verapamil reverses myocardial no-reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Cell Biochem Biophys 67 (2013), 911–914.
57. 57 Wang, L., Cheng, Z., Gu, Y., Peng, D., Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. Biomed Res Int, 2015, 2015, 382086.
58. 58 Su, Q., Nyi, T.S., Li, L., Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev, 5, 2015, CD009503.
59. 59 Fischell, T.A., Haller, S., Pulukurthy, S., Virk, I.S., Nicardipine and adenosine “flush cocktail” to prevent no-reflow during rotational atherectomy. Cardiovasc Revasc Medicine 9 (2008), 224–228.
60. 60 Fischell, T.A., Subraya, R.G., Ashraf, K., Carter, A.J., Perry, B., Haller, S.D., “Pharmacologic” distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q was MI during SVG interventions. J Invasive Cardiol 19 (2007), 58–62.
61. 61 Lambert, C.R., Pepine, C.J., Effects of intravenous and intracoronary nicardipine. Am J Cardiol 64 (1989), 8H–15H.
62. 62 Zhao, Y.J., Fu, X.H., Ma, X.X., et al. Intracoronary fixed dose nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction. Exp Ther Med 6 (2013), 479–484.
63. 63 Kobatake, R., Sato, T., Fujiwara, Y., et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels 26 (2011), 379–384.
64. 64 Parham, W.A., Bouhasin, A., Ciaramita, J.P., Khoukaz, S., Herrmann, S.C., Kern, M.J., Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation 109 (2004), 1236–1243.
65. 65 Parikh, K.H., Chag, M.C., Shah, K.J., et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol 85 (2007), 476–482.
66. 66 Su, Q., Li, L., Naing, K.A., Sun, Y., Safety and effectiveness of nitroprusside in preventing no-reflow during percutaneous coronary intervention: a systematic review. Cell Biochem Biophys 68 (2014), 201–206.
67. 67 Zhao, S., Qi, G., Tian, W., Chen, L., Sun, Y., Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention: a meta-analysis. J Interv Cardiol 27 (2014), 356–364.
68. 68 Aksu, T., Guler, T.E., Colack, A., et al. Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord, 15, 2015, 10.
69. 69 Iwakura, J., Ito, H., Okamura, A., et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J 73 (2009), 925–931.
70. 70 Kucukcelebi, A., Ozcan, M., The beneficial effect of cyclosporine-A on the no-reflow phenomenon in rat skin island flaps. Br J Plast Surg 45 (1992), 512–514.
71. 71 Cung, T.T., Morel, O., Cayla, G., et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 373 (2015), 1021–1031.
72. 72 Porto, I., Ashar, V., Mitchell, A.R., Pharmacological management of no reflow during percutaneous coronary intervention. Curr Vasc Pharmacol 4 (2006), 95–100.
73. 73 Qin, T., Xie, L., Chen, M.H., Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon. BMC Cardiovasc Disord, 13, 2013, 68.
74. 74 Zhou, S.S., Tian, F., Chen, Y.D., et al. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevations acute myocardial infarction. J Geriatr Cardiol 12 (2015), 135–142.
75. 75 Potdar, A., Sharm, S., The ‘MAP strategy’ (maximum aspiration of atherothrombus and adjunctive glycoprotein IIb/IIIa inhibitor utilization combined with prolonged inflation of balloon/stent) for preventing no-reflow in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a retrospective analysis of seventy-one cases. Indian Heart J 67 (2015), S43–S46.
76. 76 Hale, S.L., Kloner, R.A., Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion. J Thromb Thrombolysis 39 (2015), 50–54.
77. 77 Chen, W.R., Tian, F., Chen, Y.D., et al. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. Int J Cardiol 208 (2016), 109–114.
78. 78 Herring, M.J., Dai, W., Hale, S.L., Kloner, R.A., Rapid induction of hypothermia by the ThermoSuit system profoundly reduces infarct size and anatomic zone of no reflow following ischemia-reperfusion in rabbit and rat hearts. J Cardiovasc Pharmacol Ther 20 (2015), 193–202.
79. 79 Mewton, N., Thibault, H., Roubille, F., et al. Postconditioning attenuates no-reflow in STEMI patients. Basic Res Cardiol, 108, 2013, 383.
80. 80 Ovize, M., Baxter, G.F., Di Lisa, F., et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 87 (2010), 406–423.
81. 81 Freixa, X., Bellera, N., Ortiz-Pérez, J.T., et al. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J 33 (2012), 103–112.
82. 82 Hahn, J.Y., Song, Y.B., Kim, E.K., et al. Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. Circulation 128 (2013), 1889–1896.